Serotiny Appoints Chad May, Ph.D., as Chief Scientific Officer
Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.
- Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.
- In this new role, Dr. May will lead the research and development of Serotinys novel therapeutics programs.
- "Chad is a fantastic addition to the Serotiny leadership team," said Serotiny Chief Executive Officer Colin Farlow.
- Dr. May commented, "It is very exciting for me to be joining the innovative team at Serotiny.